Introduction: The present study aimed to evaluate the pharmacokinetic and pharmacodynamic properties of insulin degludec (IDeg) in Japanese patients with type 1 diabetes. Materials and Methods: This was a randomized, single-center, double-blind, two-period, crossover, multiple-dose trial. Patients were randomized into two treatment sequences, and received IDeg or insulin detemir for 6 days and a washout period (7-21 days) before switching treatment. Blood samples for pharmacokinetic measurements were obtained before each dose and up to 120 h after the last dose of each treatment period. Pharmacodynamic measurements were obtained using a 26-h euglycemic clamp procedure after the last dose of each treatment period. Results: A total of 22 patients were randomized (14 men, 8 women; mean glycosylated hemoglobin at baseline of 7.5% [based on Japanese Diabetes Society value]). At steady state, total glucose-lowering effect (area under the glucose infusion rate [GIR] curve during one dosing interval [s, 0-24 h] at steady state [AUC GIR,s,SS ]) was 1,446 mg/kg and total exposure (geometric mean) of IDeg (AUC IDeg,s,SS ) was 81,270 pmol h/L. Both the glucoselowering effect and the exposure of IDeg were evenly distributed over the dosing interval, with AUC for the first 12-h intervals being approximately 50% of the total (geometric mean; AUC GIR,0-12h,SS /AUC GIR,s,SS = 48%; AUC IDeg,0-12h,SS /AUC IDeg,s,SS = 53%). Conclusions: IDeg has a flat, consistent and ultra-long glucose-lowering effect that is evenly distributed across a 24-h interval and an ultra-long duration of action in Japanese patients with type 1 diabetes. These data support once-daily dosing of IDeg in all patients. Overall, the pharmacodynamic and pharmacokinetic end-points and safety observations are consistent with those previously reported in Caucasian patients.
INTRODUCTION
Basal insulin is an important element in the treatment of type 1 diabetes, and the use of long-acting insulin analogs as part of a basal-bolus injection regimen has resulted in significantly improved glycemic control. Reduced fasting plasma glucose and reduced all-day, severe and nocturnal hypoglycemic episodes were observed in several studies when insulin detemir (IDet) was compared with neutral protamine Hagedorn (NPH) 1, 2 . Current basal insulins can be administered once daily; however, the duration of the glucose-lowering effect can vary between patients, resulting in a requirement for twice-daily injections in many patients, particularly in patients with type 1 diabetes 3, 4 . Insulin degludec (IDeg) is a new-generation, ultra-long-acting insulin developed for once-daily administration with a distinct mechanism of protraction. On subcutaneous (SC) injection, IDeg forms multi-hexamers. These form a soluble depot in the SC tissue, from which monomers gradually separate at a consistent rate and are absorbed into the circulation 5, 6 . This mechanism of absorption leads to flat, consistent, and long pharmacokinetic and pharmacodynamic profiles in Caucasian patients 5 . In addition, IDeg has low day-to-day variability in glucose-lowering effect and fourfold lower variability within patients compared with insulin glargine (IGlar) under steadystate conditions 7 . These findings, coupled with the duration of action of IDeg, which extends beyond 42 h in Caucasian patients, suggests that a delayed or missed injection might not compromise glycemic control to the same extent as currently available basal insulins 5, 8 . Furthermore, throughout the clinical development program, IDeg was associated with significantly lower rates of nocturnal hypoglycemia at similar levels of glycemic control in type 1 diabetes compared with IGlar 9 . Thus far, no studies have reported on the pharmacokinetic and pharmacodynamic properties of IDeg in the Japanese population. As evidence suggests that drug responsiveness might be affected by race and ethnicity 10 , it is important to investigate the pharmacological properties of a drug in patients from different race and ethnic backgrounds. Subsequently, the aim of the present study was to evaluate the pharmacokinetic and pharmacodynamic properties of IDeg in Japanese patients with type 1 diabetes. Furthermore, the data from the present study will allow for comparisons with results from an earlier study in Caucasian patients.
MATERIALS AND METHODS

Study Populations
Eligible participants were Japanese men and women aged 20-65 years (inclusive), with type 1 diabetes treated with insulin for ≥12 months with a daily basal insulin requirement of ≥0.3 (I)U/kg. Eligible participants had a body mass index (BMI) of 18.0-28.0 kg/m 2 (inclusive), with glycosylated hemoglobin (HbA 1c ) levels ≤10.0% (values reported based on Japanese Diabetes Society value) and fasting C-peptide at baseline <0.3 nmol/L.
Exclusion criteria included: a history or presence of cancer or cardiovascular disease; supine blood pressure obtained at the screening visit outside the range of 90-140 mmHg for systolic blood pressure or 50-90 mmHg for diastolic blood pressure; proliferative retinopathy or maculopathy and/or severe neuropathy; recurrent severe hypoglycemia (more than one severe hypoglycemic event during the past 12 months) or hypoglycemic unawareness as judged by the investigator; or hospitalization for diabetic ketoacidosis during the previous 6 months. Patients who smoked more than five cigarettes or the equivalent per day were also excluded from this study.
Study Design
This was a single-center (Sumida Hospital, Tokyo, Japan), randomized, multiple-dose, double-blind, two-period, cross-over trial carried out in Japanese patients with type 1 diabetes (Clinical trials.gov number: NCT01135927). The protocol, any protocol amendments, the consent form, and the patient information sheet were reviewed and approved by a local institutional review board before trial initiation. Furthermore, the study was carried out in accordance with the Declaration of Helsinki and its amendments in force at the initiation of the trial, and in accordance with the Ministry of Health and Welfare (MHW) ordinance on good clinical practice (MHW Ordinance No. 28; 27 March 1997) and relevant applicable regulations. Patients were informed of the risks and benefits of the trial, and were informed that they could withdraw from the trial at any time for any reason. Consent was obtained in writing before any trial-related activities, and the investigator retained the consent forms.
Interventions and Pharmacokinetic Sampling
Individuals eligible for participation in the trial were randomized to one of the treatment sequences (either IDeg followed by IDet or IDet followed by IDeg). Both the investigator and the patients were blinded to trial treatment, and a person not otherwise involved in the trial prepared the doses. Before receiving the first dose, patients underwent a washout period during which their usual basal insulin was not taken for 48 h (for IDeg or IDet) or for at least 22 h (for NPH or other intermediate-acting insulin). Each treatment sequence included two treatment periods of 6 days of once-daily dosing of IDeg or IDet at 20.00 hours by a qualified person, followed by 5 days of pharmacokinetic blood sampling. To avoid any carry-over effect between treatment periods, the two treatment periods were separated by a washout period of 7-21 days. In addition, the patients were provided with NPH insulin (Novolin â N) to be used as basal insulin from clamp termination until the last blood sample for pharmacokinetic assessment had been taken. Patients were allowed to resume their usual insulin treatment after the last blood sample for pharmacokinetic assessment.
IDet was included primarily as a control (i.e., a comparator basal insulin analog to help evaluate treatment with IDeg) in the event that results for IDeg in Japanese patients differed from those reported previously in Caucasian patients 11 . As this was not observed, only results from IDeg treatment are reported herein. Plasma glucose level was controlled by additional bolus insulin (insulin aspart) during the treatment period (no bolus injections were administered for 10 h before dosing, and during the clamp procedure).
Blood samples for determination of serum IDeg concentration were obtained before administration of each dose. Immediately after the last dose, blood samples were taken frequently up to 36 h (at least every 1-2 h until 24 h post-dose and at 30-and 36-h time-points), with additional samples taken at 48, 72, 96 and 120 h post-dose.
Serum IDeg concentrations were measured using a specific sandwich enzyme-linked immunosorbent assay 7, [12] [13] [14] . The patients fasted (with no oral intake other than water) for 7 h before the clamp run-in period of 5 h. However, rapidly absorbable carbohydrates could be taken to prevent hypoglycemia before the clamp. Patients experiencing hypoglycemia before a clamp were rescheduled. In brief, approximately 5 h before dosing of the trial product, patients received a variable intravenous (i.v.) infusion of human insulin or 10% glucose solution to obtain a blood glucose clamp target of 5.5 mmol/L (100 mg/dL). After dosing, the i.v. insulin infusion (if any) was decreased gradually and stopped completely when blood glucose had decreased by 0.3 mmol/L (5 mg/dL); glucose infusion was then initiated to maintain the glucose concentration at the glucose clamp target of 5.5 mmol/L (100 mg/dL). The clamp continued for 26 h post-dosing of trial product, but was terminated earlier if the blood glucose exceeded 13.9 mmol/L (250 mg/mL) without any glucose having been administered for at least 30 min. During the entire clamp procedure, patients remained fasting (with no oral intake other than water) and stayed in a supine or semi-supine position.
Statistical Analysis
The full analysis set comprised all randomized patients. Statistical analyses were carried out using SAS 9.1.3 software (SAS Institute Inc., Cary, NC, USA).
The primary end-point was the area under the glucose infusion rate (GIR) curve during one dosing interval (s, 0-24 h) at steady state (AUC GIR,s,SS ) for IDeg treatment. Secondary pharmacodynamic end-points included duration of action and distribution of glucose-lowering effect across the dosing interval at steady state (AUC GIR,0-12h,SS /AUC GIR,s,SS ). Secondary pharmacokinetic end-points included total exposure (AUC IDeg,s,SS ) and distribution of exposure over the dosing interval at steady state (AUC IDeg,0-12h,SS /AUC IDeg,s,SS ). Safety end-points included adverse events (AEs), hypoglycemic episodes (hypoglycemic episodes were defined as 'confirmed' when they were either classified as 'severe' as defined by the American Diabetes Association 15 or 'minor' defined by plasma glucose <3.1 mmol/L [56 mg/dL], or verified by a full blood glucose <2.8 mmol/L [50 mg/dL]), local injection-site reactions, electrocardiogram, physical examination, vital signs and laboratory parameters. AUC GIR,s,SS was calculated as the area under the smoothed GIR profile using the linear trapezoidal technique on interpolated points. Smoothing of GIR was achieved with the Loess smoothing technique, using a fixed smoothing parameter of 0.25 and sampling with 5-min intervals. The log-transformed AUC GIR,s,SS was analyzed using an analysis of variance method, with treatment and treatment period as fixed factors, and patient as a random effect. In order to account for potential heteroscedasticity, the error variance depended on the treatment.
Secondary pharmacodynamic end-points were derived from the individual GIR (smoothed) and blood glucose profiles at steady state. All other pharmacodynamic end-points were summarized using descriptive statistics. Distribution of exposure over a 24-h dosing interval at steady state was quantified by estimating the ratio between the AUC for the first 12-h interval over the total AUC for the entire 24-h dosing interval under the GIR (AUC GIR,0-12h,SS /AUC GIR,s,SS ). In the present study, the duration of action was defined in accordance with previously published glucose clamp trials with IDeg 5 -that is, when blood glucose concentration consistently exceeded 8.3 mmol/L (150 mg/dL).
Secondary pharmacokinetic end-points were derived from insulin concentration-time curves at steady state. AUC IDeg,s,SS was calculated as the area under the insulin concentration-time profile using the linear trapezoidal technique based on observed values and actual measurement times between 0 and 24 h.
In post-hoc analyses, the time to clinical steady state for IDeg was defined as the time from first dose until serum IDeg trough concentrations exceeded 90% of the final plateau level 16 .
RESULTS
Participants
A total of 24 patients were screened, 22 patients were randomized and exposed to at least one drug administration, and 21 patients completed the trial. One patient withdrew consent after visit 10, as he/she was not able to continue to visit the site because of an unintended change of his/her schedule (personal reasons). A total of 64% of patients were male (14/22), and the mean (standard deviation [SD]) age at baseline was 42 years (12 years). Mean (SD) BMI at baseline was 22.3 kg/m 2 (2.4 kg/m 2 ), and the mean (SD) duration of diabetes among patients was 18 years (11 years). Mean (SD) HbA 1c and fasting C-peptide concentration at baseline were 7.5% (1.1%) and 0.04 nmol/L (0.03 nmol/L), respectively.
Steady-State Pharmacodynamics
At steady state, the mean 24-h GIR profile of IDeg was flat and consistent ( Figure 1 ). The mean AUC GIR,0-12h,SS /AUC GIR,s,SS was 48% ( Table 1 ), suggesting that the glucose-lowering effect of IDeg was relatively evenly distributed across the first and second 12 h of the 24-h dosing interval.
The total glucose-lowering effect of IDeg (AUC GIR,s,SS ; primary end-point) was 1,446 mg/kg (55%); geometric mean [coefficient of variation]). 
Duration of Action at Steady State
Steady-State Pharmacokinetics
IDeg trough levels (pharmacokinetic concentrations measured immediately before each dose) increased over the first days of treatment before reaching a plateau, and showed that steady state with IDeg was reached after 2-3 days of treatment in all patients, and was confirmed by post-hoc analyses (Table 2) . Total exposure with IDeg (AUC IDeg,s,SS ) was 81,270 pmol h/L and exposure to IDeg was evenly distributed across one dosing interval (Figure 2) , with a mean AUC IDeg,0-12h,SS /AUC IDeg,s,SS of 53% (Table 3) . Mean pharmacokinetic 120-h profiles obtained after the last dose showed that the serum IDeg concentration decreased slowly over time and was detectable for at least 120 h (5 days, end of observation period; data not shown).
Safety
IDeg was well tolerated, and no new safety issues were identified. Overall, three treatment-emergent AEs (other than hypoglycemia) were reported after treatment with IDeg. No serious AEs occurred; all AEs were mild in nature, and no injectionsite reactions were recorded. A total of 93 confirmed treatment-emergent hypoglycemic episodes were reported in 13 patients for IDeg.
DISCUSSION
The present study examined the pharmacokinetic and pharmacodynamic properties of IDeg in Japanese patients with type 1 diabetes. Because of the ultra-long duration of action of IDeg, relevant pharmacodynamic investigations should be carried out at steady state, as this is a more clinically relevant context. IDeg has previously been shown to reach steady state after 2-3 days of treatment 17 ; therefore, in this study, pharmacodynamic investigations were carried out on the sixth day of treatment. (%) 48 (30) Geometric mean presented. AUC GIR,s,SS , area under the glucose infusion rate curve during one dosing interval (0-24 h as 's') at steady state; CV %, coefficient of variation in percent.
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6,000 Geometric mean presented. AUC s,SS , area under the serum insulin concentration curve during one dosing interval (0-24 h as 's') at steady state; CV%, coefficient of variation in percent. ; data on file). Results from the current study also show that IDeg concentrations in Japanese patients 42 h after administration were similar to those reported in Caucasian patients with type 1 diabetes, and that IDeg was detectable in serum for at least 120 h after the last dose at steady state 5 . In addition, 24-h exposure to IDeg at a dose of 0.4 U/kg was similar in Japanese (AUC s,SS 81,270 pmol h/L) and Caucasian patients (AUC s,SS 82,612 pmol h/L) 18 . Furthermore, time to steady state for IDeg in Japanese patients was 2-3 days, which is consistent with that reported across patients of varying ethnic backgrounds 19 . As a clear relationship between exposure to IDeg and glucose-lowering effect has been shown, and as the long pharmacokinetic properties and GIR profiles of IDeg appear to be preserved in Japanese patients with type 1 diabetes, the duration of action of IDeg in this population would appear to be comparable with that observed in Caucasian patients with type 1 diabetes 5 . As expected, end of action of IDeg did not occur for any patient in the present study during the 26-h clamp period, with very little deviation from target glucose clamp level, confirming that the glucose-lowering effect of IDeg extends beyond 26 h in Japanese patients with type 1 diabetes. These findings are consistent with the data observed in Caucasian patients, where the duration of action extended beyond 42 h (the duration of euglycemic clamp) at all dose levels (0.4, 0.6 and 0.8 U/kg) in most patients investigated 5 . Several limitations must be considered due to the experimental design of the present study. In particular, the clinical environment is considerably different from the conditions of the glucose clamp procedure. Furthermore, the number of hypoglycemic events observed in the study is likely to be affected by study design, as patients received a fixed dose (0.4 U/kg) of insulin, independent of the individual patient's insulin requirements. It should be noted that, under clinical conditions, IDeg should always be titrated according to individual requirements.
The ultra-long pharmacokinetic and pharmacodynamic properties of IDeg could reduce the impact of missed insulin doses. In a 26-week clinical trial in patients with type 2 diabetes, intervals of 8-40 h were applied between IDeg doses without compromising glucose control or safety in comparison with IGlar administered once daily at the same time each day 20 . Considering that the present study shows that the pharmacokinetic and pharmacodynamic properties of IDeg are preserved in Japanese patients, the ultra-long duration of action and the flat, consistent glucose-lowering effect of IDeg could also reduce the impact of missed or mistimed doses on the efficacy and safety of IDeg in the Japanese population.
As discussed earlier, IDeg has an evenly distributed glucoselowering effect, is associated with fourfold lower day-to-day variability 7 and significantly reduced rates of nocturnal hypoglycemia compared with IGlar in type 1 diabetes with similar levels of glycemic control 9 . These findings are further supported by a separate 26-week treat-to-target study in Asian patients with type 2 diabetes, including Japanese patients, that reported a lower overall rate of hypoglycemia during the maintenance treatment period with IDeg compared with IGlar 21 .
In conclusion, IDeg has a flat and consistent glucose-lowering effect that is evenly distributed across a 24-h dosing interval in Japanese patients. IDeg has an ultra-long duration of action in Japanese patients consistent with that reported in previous studies with Caucasian patients, allowing for once-daily dosing. The same clinical benefits of IDeg, such as flexible dosing, low rates of hypoglycemia and maintenance of glycemic control (including in the event of a missed dose), are therefore expected in this population.
ACKNOWLEDGMENTS
This study was funded by Novo Nordisk. Editorial assistance was provided by ApotheCom ScopeMedical Ltd.
DISCLOSURE
II has no conflicts of interest to declare. KK is a member of advisory panels for Novo Nordisk, Sanwa Kagaku Kogyo, Takeda and Taisho Pharmaceutical Co., Ltd; has received scholarship grants from Chugai, Daiichi Sankyo, MSD, Novo Nordisk and Takeda; and has received speaker honoraria from MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Novo Nordisk, Takeda and Mitsubishi Tanabe Pharma. KH has received speaker honoraria from Novo Nordisk and Sanofi. LB and HH are employees and shareholders of Novo Nordisk.
